Mainz Biomed NV is a molecular genetics cancer diagnostic company. The firm is engaged in the developing of market-ready molecular genetic diagnostic solutions for life-threatening conditions.

Mainz Biomed (MYNZ) announced it has entered into a License and Option Agreement with Liquid Biosciences to access a portfolio of novel mRNA ...

With these developments, Mainz Biomed is now fully compliant with all Nasdaq continued listing standards and will maintain its listing and trading on the Nasdaq Capital Market. Mainz Biomed ...

Bayern Munich is once again making waves in the transfer market as they consider Mainz's 24-year-old forward, Burkhardt, as a potential backup for Harry Kane. This article will delve into Bayern’s ...

(RTTNews) - Mainz Biomed N.V. (MYNZ), a molecular genetics diagnostic company specializing in early cancer detection, announced Thursday that it has entered into an exclusive licensing agreement ...

BERKELEY, Calif. and MAINZ, Germany, March 03, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company ...

BERKELEY, Calif. - Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company with a market capitalization of $16.47 million, has entered into an exclusive licensing agreement with ...

Market Capitalization Reflects the total market value of a company. Market Cap is calculated by multiplying the number of shares outstanding by the stock's price. For companies with multiple ...